CRISPR Genome Editing Treatment for ATTR – Webinar
Jeffrey Cehelsky of Intellia provides an update on Intellia’s CRISPR/Cas9 genome editing treatment for TTR amyloidosis at ASG’s 12/05/2020 ATTR webinar.
Stay Up To Date:
Receive the latest news and developments in treatment and care